Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

[1]  A. Lash,et al.  Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. LeBlanc,et al.  Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial , 2013, Clinical Cancer Research.

[3]  J. Crowley,et al.  Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors , 2013, Clinical Cancer Research.

[4]  I. Shih,et al.  Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms , 2013, Advances in anatomic pathology.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  L. Landrum,et al.  Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[7]  Matthew D Finkelman,et al.  Patients' expectations about effects of chemotherapy for advanced cancer. , 2012, The New England journal of medicine.

[8]  B. Monk,et al.  Progress and Trends for Cancer Drug Approval – an Analysis of FDA Advisory Committee , 2012 .

[9]  A. Malpica,et al.  Ovarian low-grade serous carcinoma: a comprehensive update. , 2012, Gynecologic oncology.

[10]  L. Kiemeney,et al.  Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. , 2012, Gynecologic oncology.

[11]  Jeffrey M. Fowler,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer , 2012 .

[12]  L. Traeger,et al.  Evidence-based treatment of anxiety in patients with cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[14]  J. Thigpen,et al.  A Phase 3 Trial of Bevacizumab in Ovarian Cancer , 2012 .

[15]  J. Thigpen.  OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer , 2012 .

[16]  J. Dupuy,et al.  Effectiveness of adaptive designs for phase II cancer trials. , 2012, Contemporary clinical trials.

[17]  J. Berek,et al.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort , 2011, British Journal of Cancer.

[18]  B. Monk,et al.  Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. , 2011, Gynecologic oncology.

[19]  Boris Freidlin,et al.  Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[21]  On assessing the presence of evaluation‐time bias in progression‐free survival in randomized trials , 2011, Pharmaceutical statistics.

[22]  Christian Marth,et al.  2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference , 2011, International Journal of Gynecologic Cancer.

[23]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[24]  Sue-Jane Wang,et al.  Editorial: Adaptive Designs: Appealing in Development of Therapeutics, and Where do Controversies Lie? , 2010, Journal of biopharmaceutical statistics.

[25]  S. Cannistra.  Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Robert L. Erwin.  Therapy for advanced stage cancer: What do patients want and expect? A patient advocate's perspective. , 2010, The oncologist.

[27]  J. Thigpen.  Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer , 2010 .

[28]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[29]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[30]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Parmar,et al.  Speeding up the Evaluation of New Agents in Cancer , 2008, Journal of the National Cancer Institute.

[32]  E. Feuer,et al.  Improved survival time: What can survival cure models tell us about population‐based survival improvements in late‐stage colorectal, ovarian, and testicular cancer? , 2008, Cancer.

[33]  J. Thigpen.  Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG , 2008 .

[34]  Boris Freidlin,et al.  Proposal for the use of progression-free survival in unblinded randomized trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Marc Buyse,et al.  Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation , 2006, Pharmaceutical statistics.

[36]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[37]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[38]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[39]  E. Trimble,et al.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  M. Parmar,et al.  Clinical trials in ovarian carcinoma: study methodology. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  E. Eisenhauer,et al.  Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) , 2005 .

[42]  E. Eisenhauer,et al.  Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.

[43]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis , 2002 .

[44]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[47]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[48]  Ook.,et al.  CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER , 2000 .

[49]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.